Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 11 (2022) > Article

DOI: 10.14704/nq.2022.20.11.NQ66340

Assessment Of Serum Resistin Relation To Hepatocellular Carcinoma In Patient With Liver Cirrhosis

Mahmoud Abdou Ashour*, Fady Maher Wadea, Nader Mohamad M. Hussein, Abd-Elhalim Mohamed A. Elnagar


Background: Hepatocellular carcinoma in the most prevalent primary liver cancer and the third leading cause of cancer related mortalities worldwide. Increased serum resistin level was suspected to influence the growth and proliferation of malignant cells possibly HCC in patients with liver cirrhosis. Aim of the work: The aim of this study was to assess the possible relation between serum levels of resistin and HCC in patients suffering of liver cirrhosis.Methods: This case-control study was conducted at the gastroenterology and hepatology unit of the Internal Medicine Department of Zagazig University Hospitals for 6 months in the period from January 2021 to January 2022 on 80 patients divided into two matched groups for age and sex; cases group included 40 cirrhotic patients with HCC (their median ages were 62 years and the range was from 18 – 75 years) and a control group that included 40 cirrhotic patients without HCC (their median ages were 59 years and the range was from 48 – 72 years). Results: Regarding serum resistin level, our results showed that serum resistin level was significantly higher in cases group than in control group (19.4 vs 3.4 ng/mL) with p-value: < 0.001. There was significant positive correlation between serum resistin and total cholesterol and LDL with p-value: < 0.001. While, there was no significant correlation between serum resistin and other variables. Resistin at cutoff >13.7 with AUC of 0.942 was able to diagnose HCC with a sensitivity of 90% and a specificity of 95%.


Liver cirrhosis, Hepatocellular carcinoma, Insulin resistanca, Resistin

Full Text